What is NovoCure's stock-based comp?

NovoCure (NVCR) reported stock-based comp of $63.01M in Q1 2026.

How has NovoCure's stock-based comp changed year-over-year?

NovoCure's stock-based comp increased by 113.2% year-over-year, from $29.55M to $63.01M.

What is the long-term trend for NovoCure's stock-based comp?

Over 4 years (2021 to 2025), NovoCure's stock-based comp has grown at a 2.5% compound annual growth rate (CAGR), from $94.9M to $104.83M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

NovoCure NVCR Stock-Based Comp

Stock-Based Comp at other companies

Boston ScientificBSX

$83M+12.2%

MedtronicMDT

$95M+6.7%

Iovance Biotherapeutics, Inc.IOVA

$11.27M-50.8%

Nuvation BioNUVB

$9.03M+15.0%

Vir Biotechnology, Inc.VIR

$12.09M-14.0%

Syndax PharmaceuticalsSNDX

$12.05M+16.1%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's stock-based comp?: NovoCure (NVCR) reported stock-based comp of $63.01M in Q1 2026.
How has NovoCure's stock-based comp changed year-over-year?: NovoCure's stock-based comp increased by 113.2% year-over-year, from $29.55M to $63.01M.
What is the long-term trend for NovoCure's stock-based comp?: Over 4 years (2021 to 2025), NovoCure's stock-based comp has grown at a 2.5% compound annual growth rate (CAGR), from $94.9M to $104.83M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.